|
Site Search
|
AlphaRx to Seek China Approval of Arthritis Drug Indaflex™
publication date: Feb 1, 2008
AlphaRx (OTCBB: ALRX) has begun applying for approval of Indaflex™ in China as a treatment for osteoarthritis, with hopes that the application will be complete by April 2008. If the request is accepted, AlphaRx will conduct a clinical trial of Indaflex™ in China, enrolling 240 patients in a two-arm trial that will treat patients for four weeks. AlphaRx anticipates that the trial will be finished by Q4 of 2008. Indaflex™ is a novel formulation of a standard therapy for osteoarthritis, indomethicin. More details...
Stock Symbol: (OTCBB:ALRX)
|
Partner Events
October 11-13, 2008
Dalian, China
U.S. FDA Inspections in China
October 15, 2008
China
November 8, 2008
San Diego, CA
November 9-11, 2008
Shanghai, China
February 23-25, 2009
San Diego
>> More details...
|
